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0022-0736/© 2019 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oKeywords: Background: Currently, the eligibility for a subcutaneous implantable deﬁbrillator (S-ICD) system relies on a pre-
implant vector screening based on the automated screening tool (AST).We investigatedwhich 12-lead ECG char-
acteristics are associated with eligibility for an S-ICD in a heterogeneous population at risk for sudden cardiac
death (SCD). The goal is to determine patient eligibility for S-ICD using the standard 12-lead ECG, thereby
avoiding additional AST screening.
Methods:We evaluated the eligibility for an S-ICD in 254 consecutive patients at risk for SCD. We identiﬁed 12-
lead ECG parameters which were independently associated with AST passing (≥1 vector) using multivariable lo-
gistical regression analysis in our derivation cohort. The ﬁnal model was tested in a separate validation cohort.
Results: The overall passing rate was 92% in our derivation cohort. Independent 12-lead ECG characteristics asso-
ciated with AST passing were QRS ≤ 130 ms, absence of QRS/T discordance in lead II and R/T-ratio ≥3.5 in lead II.
Eighty-three of 254 patients (33%) fulﬁlled these three criteria and had a passing rate of 100%. Of the validation
cohort, 37 of 60 patients (62%) fulﬁlled all three criteria and also had a passing rate of 100%. The interobserver
agreement for applying the ECG model was 90% (Cohen's Kappa = 0.80).
Conclusion:Using the standard 12-lead ECG,we developed a simple screeningmodelwith a high speciﬁcity for S-
ICD eligibility. Our results suggest that patients who fulﬁll the three ECG criteria do not need additional AST-
screening.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Subcutaneous implantable cardioverter-
deﬁbrillator
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The efﬁcacy and safety of the subcutaneous implantable deﬁbrillator
(S-ICD) has been demonstrated in both primary and secondary preven-
tion of sudden cardiac death (SCD) [1]. However, the advantage of the S-
ICD is partially offset by the presence of inappropriate shocks that is
mainly attributed to T-wave oversensing [1–4]. Therefore, it is recom-
mended that every S-ICD candidate needs to be screened before S-ICD
implantation to reduce the likelihood of T-wave oversensing. In current
practice, the eligibility for a subcutaneous implantable deﬁbrillator sys-
tem relies on a pre-implant vector screening based on the automated
screening tool (AST). Several studies have investigated the feasibility
of AST for S-ICD eligibility screening [5–7].
Previous studies demonstrated several standard 12-lead ECG char-
acteristics associatedwith the eligibility for an S-ICD. However, these as-
sociations were based on the manual ECG screening tool [8–10]. Werasmus MC, University Medical
rdam, the Netherlands.
. This is an open access article underinvestigatedwhich12-leadECGcharacteristics are associatedwith eligi-
bility for an S-ICD in a heterogeneous population at risk for sudden car-
diac death (SCD). The goal is to determine patient eligibility for S-ICD
using the standard 12-lead ECG, thereby avoiding additional AST
screening. Quick assessment of eligibility for an S-ICD based on a stan-
dard 12-lead ECGmay be useful as the healthcare provider immediately
knows if a patient is eligible for an S-ICD.
Methods
Study design
This was a retrospective study evaluating 12-lead ECG characteris-
tics associatedwith AST passing in consecutive patients with cardiomy-
opathy, congenital heart disease, and inherited primary heart disease.
The purpose of the present study was to develop a 12-lead ECG screen-
ing model which can identify patients who are eligible for an S-ICD,
thereby omitting additional AST screening. The standard 12-lead ECG
was acquired directly after the AST-screening. A patient was considered
eligible for S-ICD if at least one sensing vector passed the AST in boththe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Demographics and clinical characteristics.
Total
(n= 254)
Pass
(n = 233)
Fail
(n = 21)
P-value
Male gender (%) 167 (66) 154 (66) 13 (62) 0.70
Age, years, ±SD 51 ± 16 51 ± 16 56 ± 16 0.17
BMI, kg/m2, ±SD 26.1 ± 4.5 26.0 ± 4.5 26.5 ± 5.0 0.68
Implantable
cardioverter-deﬁbrillator
110 (43) 103 (44) 7 (33) 0.36
Primary prevention 70 (28) 65 (28) 5 (24) 0.69
Secondary prevention 40 (16) 38 (16) 2 (10) 0.41
Cardiac diagnosis⁎
Structural heart disease (%) 194 (76) 175 (75) 19 (90) 0.11
Cardiomyopathy 126 (50) 115 (49) 11 (52) 0.79
Congenital heart disease 68 (27) 60 (26) 8 (38) 0.22
Inherited primary arrhythmia
syndrome (%)
60 (24) 58 (25) 2 (10) 0.11
Data are presented as mean ± SD, categorical data as n (%). BMI: body-mass index.
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derivation cohort. This derivation cohort consisted of 254 patients
whichwaspreviously describedby our group [7]. In this studywe inves-
tigated the eligibility for S-ICD using both AST and manual ECG screen-
ing. In brief, all consecutive patients at risk for SCD were screened for
their eligibility for S-ICD during their routine outpatient clinic using
both AST and manual ECG screening between February and June 2017.
Exclusion criteria were ≥3% ventricular pacing, cardiac
resynchronization therapy and patients with paced QRS-complex dur-
ing screening.
Finally, the derived 12-lead ECG screening model was tested in an
independent validation cohort consisting of implantable cardioverter
deﬁbrillator (ICD) candidates who underwent AST-screening in a clini-
cal setting after June 2017. All included patients provided informed con-
sent to participate in the study, and the study was approved by the
institutional review board of the Erasmus Medical Center (MEC 2017-
035).
ECG analysis
Standard 12-lead ECG characteristics, such as PR interval, QRS dura-
tion, presence of interventricular conduction delay and QT(c) interval
(as determined by Fridericia formula), JTc (JTc = QTc−QRS duration)
were extracted from the baseline standard 12-lead ECG. Furthermore,
maximum QRS and T-wave amplitude (absolute maximum deﬂection
from the isoelectric line), absence of T-wave inversion (TWI) and QRS/
T-wave discordance, and R/T-ratio were manually determined using
E-scribe software (E-scribe™ ECG Workstation version 8.16.1). The
characteristics were speciﬁcally analyzed in lead I, II and aVF, since
these leads have a vector direction which are comparable to the pri-
mary, secondary and alternate sensing vector of the S-ICD, respectively.
T-wave was considered inverted when the highest amplitude had a
negative polarity and QRS/T-wave discordance was noticed when the
T-wave had an opposite direction as the QRS complex. For the purpose
of determining TWI and QRS/T-wave discordance the T-wave should be
≥0.1 mV.
ECG characteristics of the patients who passed the AST were com-
pared to the patients who failed. Furthermore, a speciﬁc vector-based
analysis was performed to investigate which ECG characteristics were
associated with eligibility for S-ICD at the corresponding vector level.
Statistical analysis
Continuous data are presented as mean ± standard deviation or as
median with interquartile range (25th and 75th percentile), where ap-
propriate. Categorical variables are presented by frequencies and per-
centages. Differences between groups were analyzed with the
unpaired Student's t-test, Chi-square test or the Fisher's exact test, as
appropriate. Univariable and multivariable logistic regression analysis
were performed to identify factors associated with AST passing. Any
univariable variable with a P-value b0.05was entered in amultivariable
forward conditional model. Inter-observer agreement between 2 ob-
servers (RS and SCY) was evaluated using Cohen's Kappa statistics. A
P-value b0.05 was considered statistically signiﬁcant. Statistical analy-
ses were performed using SPSS version 24.
Results
Baseline characteristics
A total of 254 consecutive patients were screened for their S-ICD el-
igibility using the AST. Among them 167 (66%) patients weremales and
themean age of the study populationwas of 51±16 years. Themajority
of the patients had structural heart disease (SHD; n = 194, 76%).
Inherited primary arrhythmia syndrome (IPAS) was present in 60
(24%) patients. Hundred and ten (43%) patients had an ICD at the timeof enrollment. The majority (64%) of the indications were for primary
prevention.
Comparative demographic and clinical characteristics of those who
passed (n = 233, 92%) and those who failed (n = 21, 8%) the AST are
listed in Table 1. The passing rate varied from 83% for hypertrophic car-
diomyopathy (HCM) to 100% for long QT syndrome (LQTS). There were
no statistically signiﬁcant differences in demographics, ICD indication,
and underlying etiology between patients who passed and those who
failed the screening. Detailed overview of the baseline characteristics
has been previously reported by Sakhi et al. [7]
Patient based ECG analysis
ECG characteristics stratiﬁed by S-ICD eligibility are listed in Table 2.
Patients who passed the screening had a higher proportion of QRS
≤ 130 ms and QTc ≤ 450 ms in comparison to those who failed the
screening. When looking at speciﬁc leads, the patients who passed the
screening had less TWI in lead II; less QRS/T-wave discordance in lead
II and aVF; and a higher R/T-ratio in lead II and aVF in comparison to
those who failed the screening.
Vector-based ECG analysis
The primary, secondary and alternate sensing vectors of 254 pa-
tients, both supine and sitting postures, were analyzed separately,
resulting in 762 vectors. The primary sensing vector was the most ap-
propriate (80%, n = 204), followed by the secondary vector (77%, n
=196) and the alternate vector (59%, n=151). Results of the absolute
QRS amplitude and R/T-ratio of lead I, lead II and lead aVF with the cor-
responding vectors are demonstrated in Fig. 1. Patients who passed the
secondary or alternate vector had a higher absolute QRS amplitude in
their corresponding leads (lead II and aVF, respectively) in comparison
to those who failed (lead II: 0.92 mV versus 0.66 mV, P b 0.01; lead
aVF: 0.81 mV versus 0.53 mV, P b 0.01). Furthermore, they also had a
higher R/T-ratio in leads II and aVF (lead II: 3.88 versus 2.50, P b 0.01;
lead aVF: 4.77 versus 2.82, P b 0.01). A R/T-ratio of ≥3.5 was deemed
as the optimal cutoff based on the highest sensitivity and speciﬁcity
for the speciﬁc leads (Fig. 1). A more detailed overview of ECG charac-
teristics with the matching screening vectors are provided in supple-
mentary material (Appendix A). Patients who passed the screening
had a higher proportion of R/T-ratio ≥ 3.5 in lead II and aVF (Table 2).
ECG characteristics associated with S-ICD eligibility
Univariable and multivariable analysis for S-ICD eligibility are pre-
sented in Table 3. Univariable analysis demonstrated that QRS duration
≤130 ms, QTc duration ≤450 ms, absence of TWI in lead I and lead II,
Table 2
Baseline 12-lead ECG characteristics.
Total (n = 254) Pass (n = 233) Fail (n = 21) P-value
Sinus rhythm
(%)
229 (90) 209 (90) 20 (95) 0.41
PR interval
(IQR)a
169 (152–189) 168 (151–187) 188 (161–193) 0.06
QRS ≤ 130 ms 200 (79) 193 (83) 7 (33) b0.01
QT ≤ 450 ms 227 (89) 210 (90) 17 (81) 0.19
QTc ≤ 450 ms 223 (88) 208 (89) 15 (71) 0.02
JTc duration 294 (275–316) 295 (275–316) 289 (273–322) 0.36
Maximal QRS amplitude in mV (IQR)
- Lead I 0.72 (0.49–0.99) 0.70 (0.49–0.99) 0.88 (0.55–1.00) 0.34
- Lead II 0.87 (0.60–1.18) 0.89 (0.63–1.20) 0.63 (0.45–1.01) 0.08
- Lead aVF 0.71 (0.48–1.00) 0.72 (0.50–1.03) 0.58 (0.34–0.87) 0.36
Absence of T-wave inversion (%)
- Lead I 211 (83) 197 (85) 14 (67) 0.04
- Lead II 225 (89) 210 (90) 15 (71) 0.02
- Lead aVF 215 (85) 200 (86) 15 (71) 0.09
Absence of QRS/T-wave discordance (%)
- Lead I 179 (70) 167 (72) 12 (57) 0.16
- Lead II 198 (78) 188 (81) 10 (48) b0.01
- Lead aVF 163 (64) 156 (67) 7 (33) b0.01
R/T-ratio per lead (IQR)
- Lead I 3.87 (2.58–6.85) 3.88 (2.59–6.94) 3.44 (2.56–5.54) 1.00
- Lead II 3.52 (2.33–5.71) 3.61 (2.42–5.94) 2.52 (1.58–3.10) 0.02
- Lead aVF 3.66 (2.33–6.84) 4.08 (2.38–7.09) 2.36 (1.42–3.60) 0.02
R/T-ratio of ≥3.5 per lead (%)
- Lead I 149 (59) 139 (60) 10 (48) 0.28
- Lead II 128 (50) 123 (53) 5 (24) 0.02
- Lead aVF 136 (54) 130 (56) 6 (29) 0.02
IQR = Interquartile range.
a Only in patients with sinus rhythm.
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≥3.5 in II and aVF were associated with AST passing based on ≥1-vector
pass rule. Independent ECG characteristics associated with AST passingFig. 1. Eligibility for S-ICD of the different screening vectors based on the QRS-ampwere QRS ≤ 130ms, absence of QRS/T-wave discordance in lead II and R/
T-ratio ≥3.5 in lead II.
When applying the ECG criteria in the derivation cohort, 83 patients
(33%) fulﬁlled all three ECG criteria. In these patients, the eligibility for
S-ICD based on ≥1 vector passing rate was 100%. When using the
more stringent ≥2 vector pass criteria for S-ICD eligibility, the passing
rate was 96%.
Validation analysis
The 12-lead ECG screening model was evaluated in a validation co-
hort consisting of 60 ICD candidates who underwent AST-screening as
part of their clinical workup for ICD implantation. The mean age of the
validation cohort was 49 ± 17 years and the majority of the patients
weremale (76%). In total, 50 patients had SHD(83%) and IPASwas pres-
ent in 10 (17%) patients. The ≥1 vector pass rate was 90% for this cohort,
6 patients (10%) failed the AST screening. When applying the derived
screening model, 37 of 60 patients (62%) fulﬁlled all three 12-lead
ECG criteria. The ≥1 vector pass rate was 100% for this selected cohort,
thus all patients who fulﬁlled the three ECG criteria were eligible for
S-ICD. Furthermore, when using the stringent criteria for S-ICD eligibil-
ity (≥2 vector pass rule) the eligibility increased from 78% to 89% in pa-
tients. The interobserver agreement of the screening model was good
with a Cohen's Kappa of 0.80 and an overall agreement of 90%.
Follow-up of S-ICD patients
Of the patients who fulﬁlled all the three ECG criteria in the deriva-
tion cohort, 18 of 83 patients (22%) had an S-ICD. During a median
follow-up of 66 months (interquartile range: 35–85 months), two pa-
tients experienced an inappropriate shock. One patient received an in-
appropriate shock due to R-wave attenuation and the other patient
due to a supraventricular tachyarrhythmia detected in the shock zone.
In the validation cohort, 28 of the 37 patients (76%) who fulﬁlled the
three ECG criteria received an S-ICD and during a median follow-up oflitude and R/T-ratio of the corresponding leads. NS = no signiﬁcant p-value.
Table 3
ECG characteristics associated with S-ICD eligibility.
Variables Univariable Multivariable
OR (95% CI) P-value OR (95% CI) P-value
QRS ≤ 130 ms 9.65 (3.66–25.43) b0.01 8.09 (2.88–22.77) b0.01
QTc ≤ 450 ms 3.33 (1.18–9.54) 0.02
Absence of T-wave inversion in lead I 2.74 (1.03–7.25) 0.04
Absence of T-wave inversion in lead II 3.65 (1.29–10.33) 0.02
Absence of QRS/T-wave discordance in lead II 5.05 (1.98–12.92) b0.01 4.19 (1.49–11.74) b0.01
Absence of QRS/T-wave discordance in lead aVF 3.95 (1.53–10.19) b0.01
R/T-ratio ≥ 3.5 in lead II 3.58 (1.27–10.01) 0.02 4.21 (1.27–13.95) 0.02
R/T-ratio ≥ 3.5 in lead aVF 3.16 (1.18–8.42) 0.02
OR = odds ratio; CI = conﬁdence interval.
126 R. Sakhi et al. / Journal of Electrocardiology 55 (2019) 123–12711months (interquartile range: 3–15months) none of the patients ex-
perienced an inappropriate shock.
Discussion
The present study demonstrated that QRS duration ≤130 ms, ab-
sence of QRS/T-wave discordance in lead II and R/T-ratio ≥3.5 in lead II
were independently associated with eligibility for S-ICD based on AST-
screening. Interestingly, the eligibility for S-ICD was 100% in patients
who fulﬁlled all three criteria in both the derivation and validation
cohort.
Using the AST as a pre-implant screening tool, eligibility rates from
92% to 96% have been reported [5–7]. The study by Francia et al., re-
ported eligibility rates of 94% and 80% when using ≥1-vector and ≥2-
vector pass rule, respectively [5]. This is in line with the results of the
present study (92% for ≥1-vector pass and ≥ 80% 2-vector pass). More
recently, Bogeholz et al., found a ≥1-vector AST passing rate of 94% inFig. 2. Proposed screening procedure for S-ICD screening in daily clinical practice. CRT = ca
implantable cardioverter deﬁbrillator.33 consecutive patients who already had an S-ICD system implanted
[6]. Comparable results were demonstrated by Sakhi et al., in S-ICD pa-
tients in whom eligibility for S-ICD had already been determined with
manual ECG screening (n= 35, 100% ≥1-vector pass rule) [7].ECG characteristics associated with S-ICD eligibility
Previous studies have identiﬁed 12-lead ECG characteristics associ-
ated with S-ICD ineligibility based on manual ECG screening, such as
prolonged QRS duration, low R/T-ratio, T-wave inversion and QRS/T-
wave discordance [8–10]. Considering the high agreement between
manual ECG screening and AST on a patient level, one would expect
the same factors to be associated with S-ICD ineligibility based on AST
[7]. We identiﬁed similar factors associated with S-ICD ineligibility:
prolonged QRS duration, presence of QRS/T-wave discordance in lead
II, and low R/T-ratio in lead II. Bogeholz et al. also demonstrated thatrdiac resynchronization therapy; VT = ventricular tachycardia; TV-ICD = transvenous
127R. Sakhi et al. / Journal of Electrocardiology 55 (2019) 123–127prolonged QRS duration, presence of T-wave inversion and a low R/T-
ratio were more common in patients who failed AST-screening.
The purpose of AST screening is to select patients who are at low risk
of T-wave oversensing. Our proposed screening model achieves the
same result albeit at the cost of sensitivity (patients who fail our screen-
ing model, may still be suitable based on AST). The identiﬁed ECG fac-
tors are probably associated with a normal repolarization with a good
signal-to-noise ratio. It is known that prolonged QRS duration and
QRS/T-wave discordance are associated with repolarization abnormali-
ties. By excluding patients with repolarization abnormalities and a low
R/T-ratio, it seems logical that the chance of T-wave oversensing is low.
Clinical implications
When a patient is a potential ICD candidate and does not have an in-
dication for pacing, biventricular pacing or ATP then the patient is a po-
tential candidate for an S-ICD. In clinical practice, a potential S-ICD
candidate undergoes vector screening using AST and when at least 1
vector is suitable then we will discuss the pros and cons of transvenous
and subcutaneous ICDs. Based on previous studies it is known that the
S-ICD eligibility rate based on AST is relatively high (N90%). Some im-
planters have argued to abolish vector screening considering this high
passing rate. Unfortunately, inappropriate shocks due to T-wave
oversensing do occur and this should be prevented. We developed a
simple screening model using the standard 12-lead ECG which can
identify patients who have a very high likelihood to pass the vector
screening based on AST. When patients fulﬁll all three ECG criteria, it
seems safe to omit vector screening considering the 100% ≥1 vector
passing rate and even 96% ≥2 vector passing rate. Despite the excellent
speciﬁcity (100%), the sensitivity of the proposed screening model var-
ied between 36 and 67%. Thismeans that a substantial proportion of ICD
candidates still requires AST screening. Based on the results of the pres-
ent study, we propose a simple ﬂowchart to determine eligibility for an
S-ICD that can be easily implemented in daily clinical practice (Fig. 2).
Study limitations
Several limitations are important to highlight. It has been previously
shown that S-ICD screening during exercise can identify T-wave
oversensing and results in a greater failure rate, especially in certain pa-
tients with HCM [3,11,12]. We did not test our study population during
exercise, therefore we cannot draw conclusions on the validity of our
model in patients undergoing exercise testing as part of the screening.
Furthermore, the combination of the small number of patients in the
validation cohort and high passing rate may affect the accuracy of the
speciﬁcity of our model. Therefore, the 12-lead ECG screening model
should be validated in a larger population before widespread clinical
adoption. Finally, the safety of the proposed algorithm can be evaluated
when comparing the inappropriate shock rates of patient populations
screened with the proposed algorithm versus AST only.
Conclusion
Using the standard 12-lead ECG we developed a simple screening
model with a high speciﬁcity for S-ICD eligibility. Our results suggestthat patients who fulﬁll the three ECG criteria do not need additional
AST-screening.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.jelectrocard.2019.05.014.
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